Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer

被引：0
|
作者：
Matti S. Aapro
Stephen Chaplin
Paul Cornes
Sebastian Howe
Hartmut Link
Natalia Koptelova
Andrea Mehl
Mario Di Palma
Bridgette Kanz Schroader
Robert Terkola
机构：
[1] Genolier Cancer Center,Gustave Roussy
[2] Xcenda UK,undefined
[3] Comparative Outcomes Group,undefined
[4] Sandoz International GmbH,undefined
[5] Private Practice Hematology Oncology Kaiserslautern,undefined
[6] Paris-Saclay University,undefined
[7] Xcenda LLC,undefined
[8] a Cencora company,undefined
[9] University Medical Center,undefined
[10] Paracelsus Medical University,undefined
来源：
Supportive Care in Cancer | 2023年 / 31卷
关键词：
Febrile neutropenia; Cost-effectiveness; Filgrastim; Biosimilar; Pegfilgrastim;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] An exploratory comparative effectiveness analysis of febrile neutropenia incidence among patients with cancer receiving granulocyte colony stimulating factors.
    Pawloski, Pamala A.
    Lockhart, Catherine
    Vazquez-Benitez, Gabriela
    Defor, Terese A.
    Mendelsohn, Aaron
    Marshall, James
    Moyneur, Erick
    McDermott, Cara L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 408 - 408
  • [42] The economics of febrile neutropenia: Implications for the use of colony-stimulating factors
    Lyman, GH
    Kuderer, N
    Greene, J
    Balducci, L
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (12) : 1857 - 1864
  • [43] Colony-stimulating factors for chemotherapy-induced febrile neutropenia
    Mhaskar, Rahul
    Clark, Otavio Augusto Camara
    Lyman, Gary
    Botrel, Tobias Engel Ayer
    Paladini, Luciano Morganti
    Djulbegovic, Benjamin
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (10):
  • [44] The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia
    Jean Klastersky
    Harry Raftopoulos
    Bernardo Rapoport
    Supportive Care in Cancer, 2013, 21 : 1793 - 1795
  • [45] COST-EFFECTIVENESS OF GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) IN PRIMARY (PP) AND SECONDARY PROPHYLAXIS (SP) OF FEBRILE NEUTROPENIA (FN) IN PATIENTS WITH STAGES 2 AND 3 BREAST CANCER (BC) UNDERGOING CYTOTOXIC CHEMOTHERAPY IN FRANCE
    Perrier, L.
    Bachelot, T.
    Leon, N.
    Maurel, F.
    Cohen-Nizard, S.
    De Liege, F.
    De Liege, F.
    VALUE IN HEALTH, 2011, 14 (07) : A448 - A448
  • [46] The MASCC Neutropenia, Infection and Myelosuppression Study Group evaluates recent new concepts for the use of granulocyte colony-stimulating factors for the prevention of febrile neutropenia
    Klastersky, Jean
    Raftopoulos, Harry
    Rapoport, Bernardo
    SUPPORTIVE CARE IN CANCER, 2013, 21 (06) : 1793 - 1795
  • [47] Febrile neutropenia primary prophylaxis with granulocyte-colony stimulating factors (G-CSF) in breast cancer
    Younis, T.
    Rayson, D.
    Skedgel, C.
    CANCER RESEARCH, 2013, 73
  • [48] Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
    Advani, S. H.
    Achreckar, Suvarna
    Thomas, Dennis
    Krishnankutty, Binny
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2010, 31 (03) : 79 - 82
  • [49] Impact of granulocyte colony-stimulating factors on febrile neutropenia risk during early-stage breast cancer treatment
    Ben Abdallah, S. S.
    Letarte, N.
    Messier, C.
    Charpentier, D.
    Yelle, L.
    Younan, R.
    Bestawros, A.
    CANCER RESEARCH, 2013, 73
  • [50] The cost-effectiveness of primary prophylaxis with granulocyte colony-stimulating factor in docetaxel-containing adjuvant chemotherapy in early breast cancer: The impact of risk of febrile neutropenia and its mortality
    Chan, K. K.
    Trudeau, M. E.
    Eisen, A.
    Verreault, J. L.
    Freedman, C. A.
    Dent, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345